MTA2 Antibody#15793,Cell Signaling Technology (CST),15793

MTA2 Antibody recognizes endogenous levels of total MTA2 protein. This antibody does not cross-react with other MTA proteins. This antibody detects a 50 kDa band of unknown origin in rat cell lysates.

Reactivity

Human, Mouse, Rat, Monkey

Application

Western Blotting: 1:1000

Platform ID

BAB176071061

Cell Signaling Technology (CST)

Headquarters

3 Trask Lane Danvers, MA 01923

Contact

Tel: 877-616-2355,978-867-2388
Fax: 877-616-2355

Product Specifications
Scientific Background
Synonyms

Specifications

NameMTA2 Antibody#15793
Cat. No.15793
Accession NumberO94776
Gene ID (Entrez)94776, 9219
SensitivityEndogenous
ReactivityHuman, Mouse, Rat, Monkey
ApplicationWestern Blotting: 1:1000
Molecular Weight75
FormulationSupplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C.Do not aliquot the antibody.
StorageSupplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C.Do not aliquot the antibody.
Regulatory StatusResearch Use Only

Scientific Background

MTA2 is a component of the NuRD deacetylase complex, which is recruited by MBD3 and modulates the enzymatic activity of the histone deacetylase core (1,2). MTA2 is highly related to MTA1, but both proteins exist in biologically distinct complexes, with MTA2 being associated with complexes containing Sin3a and CHD4 (3) MTA2 has been shown to bind ERα and repress its activity and contributes to estradiol- and tamoxifen-resistant breast cancers (4). Indeed, the MTA proteins are critical regulators of many biological functions in both cancer and non-cancer settings (5,6). MTA2 upregulation has been reported in a multitude of cancers, including hepatocellular carcinomas, colorectal cancers, gastric cancers, and esophageal cancers (7-10). MTA2 has also been described in B cell development, where it interacts with Aiolos and Ikaros to control target genes (11).Zhang, Y. et al. (1999)Genes Dev13, 1924-35.Saito, M. and Ishikawa, F. (2002)J Biol Chem277, 35434-9.Yao, Y.L. and Yang, W.M. (2003)J Biol Chem278, 42560-8.Cui, Y. et al. (2006)Mol Endocrinol20, 2020-35.Sen, N. et al. (2014)Cancer Metastasis Rev33, 869-77.Kumar, R. and Wang, R.A. (2016)Gene582, 112-21.Shi, W. et al. (2015)Int J Clin Exp Pathol8, 13083-9.Ding, W. et al. (2015)Int J Clin Exp Pathol8, 7173-80.Zhou, C. et al. (2013)Mol Cancer12, 102.Liu, Y.P. et al. (2012)Exp Ther Med3, 745-749.Lu, X. et al. (2019)Cell Rep28, 472-485.e5.Alternate NamesDKFZp686F2281; metastasis -associated gene 1-like 1; metastasis associated 1 family member 2; metastasis associated 1 family, member 2; metastasis associated gene family, member 2; Metastasis-associated 1-like 1; metastasis-associated protein 2; Metastasis-associated protein MTA2; MTA1-L1 protein; MTA1L1; MTA2; p53 target protein in deacetylase complex; PID

Synonyms

DKFZp686F2281; metastasis -associated gene 1-like 1; metastasis associated 1 family member 2; metastasis associated 1 family, member 2; metastasis associated gene family, member 2; Metastasis-associated 1-like 1; metastasis-associated protein 2; Metastasis-associated protein MTA2; MTA1-L1 protein; MTA1L1; MTA2; p53 target protein in deacetylase complex; PID

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.